What should be considered on design of a colon-specific prodrug?

Expert Opinion on Drug Delivery

Volumn 7, Issue 2, 2010, Pages 245-258

  Jung, Yunjin ^a   Kim, Young Mi ^a  

^a Pusan National University   (South Korea)

Author keywords

Colon specific carrier; Colon specific prodrug; Colonic metabolism; Drug delivery; Intestinal microflora; Oral drug delivery; Prodrug and site specific drug delivery

Indexed keywords

9 AMINOCAMPTOTHECIN; ANTHELMINTIC AGENT; ANTIINFLAMMATORY AGENT; CALCITONIN; CELECOXIB; CYCLODEXTRIN; CYCLOOXYGENASE 2 INHIBITOR; DEXTRAN; FLUOROURACIL; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INSULIN; KETOPROFEN; MEBENDAZOLE; MENTHOL; MESALAZINE; METRONIDAZOLE; NALIDIXIC ACID; NALMEFENE; NALOXONE; NAPROXEN; POLYASPARTIC ACID; POLYMER; PRODRUG; RUTOSIDE; SENNOSIDE; SULFANILAMIDE DERIVATIVE; SULFATE; URSODEOXYCHOLIC ACID; VASOPRESSIN;

COLON; DRUG ABSORPTION; DRUG ACTIVITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SPECIFICITY; DRUG STABILITY; DRUG TRANSPORT; GASTROINTESTINAL TRACT; HUMAN; HYDROPHILICITY; INTESTINE FLORA; LARGE INTESTINE; NONHUMAN; OXIDATION REDUCTION REACTION; REPRODUCIBILITY; REVIEW; SMALL INTESTINE;

ADMINISTRATION, ORAL; CHEMISTRY, PHARMACEUTICAL; COLON; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MOLECULAR STRUCTURE; PRODRUGS;

EID: 76149128701     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903490401     Document Type: Review

References (105)

1. Braun K, Pipkorn R, Waldeck W. Development and characterization of drug delivery systems for targeting mammalian cells and tissues: a review. Curr Med Chem 2005;12:1841-1858
2. Langer R. Drug delivery and targeting. Nature 1998;392:5-10
3. Ruoslahti E. Drug targeting to specific vascular sites. Drug Discov Today 2002;7:1138-1143
4. Ast G. Drug-targeting strategies for prostate cancer. Curr Pharm Des 2003;9:455-466
5. Haas M, Moolenaar F, Meijer DK, et al. Specific drug delivery to the kidney. Cardiovasc Drugs Ther 2002;16:489-496
6. de Boer AG, Gaillard PJ. Drug targeting to the brain. Annu Rev Pharmacol Toxicol 2007;47:323-355
7. Takahashi-Nishioka T, Yokogawa K, Tomatsu S, et al. Targeted drug delivery to bone: pharmacokinetic and pharmacological properties of acidic oligopeptide-tagged drugs. Curr Drug Discov Technol 2008;5:39-48
8. Wilding I. Site-specific drug delivery in the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst 2000;17:557-620
9. Pavan B, Dalpiaz A, Ciliberti N, et al. Progress in drug delivery to the central nervous system by the prodrug approach. Molecules 2008;13:1035-1065
10. Shareef MA, Khar RK, Ahuja A, et al. Colonic drug delivery: an updated review. AAPS PharmSci 2003;5:E17
11. Singh Y, Palombo M, Sinko PJ. Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem 2008;15:1802-1826
12. Jain SK, Jain A. Target-specific drug release to the colon. Expert Opin Drug Deliv 2008;5:483-498
13. Patel M, Shah T, Amin A. Therapeutic opportunities in colon-specific drug-delivery systems. Crit Rev Ther Drug Carrier Syst 2007;24:147-202
14. Friend DR. Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 1998;12:591-603
15. Sinha V, Singh A, Kumar RV, et al. Oral colon-specific drug delivery of protein and peptide drugs. Crit Rev Ther Drug Carrier Syst 2007;24:63-92
16. Saffran M, Kumar GS, Savariar C, et al. A new approach to the oral administration of insulin and other peptide drugs. Science 1986;233:1081-1084
17. Bussemer T, Otto I, Bodmeier R. Pulsatile drug-delivery systems. Crit Rev Ther Drug Carrier Syst 2001;18:433-458
18. Kinget R, Kalala W, Vervoort L, et al. Colonic drug targeting. J Drug Target 1998;6:129-149
19. Van den Mooter G. Colon drug delivery. Expert Opin Drug Deliv 2006;3:111-125
20. Friend DR. New oral delivery systems for treatment of inflammatory bowel disease. Adv Drug Deliv Rev 2005;57:247-265
21. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci 2003;6:33-66
22. Sinha VR, Kumria R. Colonic drug delivery: prodrug approach. Pharm Res 2001;18:557-564
23. Chae SY, Jang MK, Nah JW. Influence of molecular weight on oral absorption of water soluble chitosans. J Control Release 2005;102:383-394
24. Ungell AL, Nylander S, Bergstrand S, et al. Membrane transport of drugs in different regions of the intestinal tract of the rat. J Pharm Sci 1998;87:360-366
25. Doh MJ, Jung YJ, Kim I, et al. Synthesis and in vitro properties of prednisolone 21-sulfate sodium as a colon-specific prodrug of prednisolone. Arch Pharm Res 2003;26:258-263
26. Jung YJ, Lee JS, Kim YM. Synthesis and in vitro/in vivo evaluation of 5-aminosalicyl-glycine as a colon-specific prodrug of 5-aminosalicylic acid. J Pharm Sci 2000;89:594-602
27. Friend DR, Chang GW. A colon-specific drug-delivery system based on drug glycosides and the glycosidases of colonic bacteria. J Med Chem 1984;27:261-266
28. Minami K, Hirayama F, Uekama K. Colon-specific drug delivery based on a cyclodextrin prodrug: release behavior of biphenylylacetic acid from its cyclodextrin conjugates in rat intestinal tracts after oral administration. J Pharm Sci 1998;87:715-720
29. Harboe E, Larsen C, Johansen M, et al. Macromolecular prodrugs. XV. Colon-targeted delivery-bioavailability of naproxen from orally administered dextran-naproxen ester prodrugs varying in molecular size in the pig. Pharm Res 1989;6:919-923
30. Leopold CS, Friend DR. In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery. J Pharmacokinet Biopharm 1995;23:397-406
31. Brown JP, McGarraugh GV, Parkinson TM, et al. A polymeric drug for treatment of inflammatory bowel disease. J Med Chem 1983;26:1300-1307
32. Sakuma S, Lu ZR, Kopeckova P, et al. Biorecognizable HPMA copolymer-drug conjugates for colon-specific delivery of 9-aminocamptothecin. J Control Release 2001;75:365-379
33. Wiwattanapatapee R, Lomlim L, Saramunee K. Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid. J Control Release 2003;88:1-9
34. Scheline RR. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol Rev 1973;25:451-523
35. Haeberlin B. FDR. Anatomy and physiology of the gastrointestinal tract: Implication for colonic drug delivery. In: Friend DR, editor, Oral colon-specific drug delivery. CRC Press, Inc., Boca Raton, FL; 1992. p. 1-43
36. Brown JP. Reduction of polymeric azo and nitro dyes by intestinal bacteria. Appl Environ Microbiol 1981;41:1283-1286
37. Faigle JW. Drug metabolism in the colon wall and lumen. In: Bieck PR, editor, Colonic drug absorption and metabolism. Marcel Dekker, Inc.; 1993. p. 29-54
38. Sinha VR, Kumria R. Microbially triggered drug delivery to the colon. Eur J Pharm Sci 2003;18:3-18
39. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003;361:512-519
40. Keighley MR, Arabi Y, Dimock F, et al. Influence of inflammatory bowel disease on intestinal microflora. Gut 1978;19:1099-1104 (Pubitemid 9087370)
41. Carrette O, Favier C, Mizon C, et al. Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease. Dig Dis Sci 1995;40:2641-2646
42. Bhat P, Shantakumari S, Rajan D, et al. Bacterial flora of the gastrointestinal tract in southern Indian control subjects and patients with tropical sprue. Gastroenterology 1972;62:11-21
43. Egan LJ, Sandborn WJ. Drug therapy of inflammatory bowel disease. Drugs Today (Barc) 1998;34:431-446
44. Kim D, Hong S, Jung S, et al. Synthesis and Evaluation of N-Nicotinoyl-2-{2-(2-Methyl-5-Nitroimidazol-1-yl) Ethyloxy}-D,L-Glycine as a Colon-Specific Prodrug of Metronidazole. J Pharm Sci 2009;98(11):4161-4169
45. Lee JS, Jung YJ, Doh MJ, et al. Synthesis and properties of dextran-nalidixic acid ester as a colon-specific prodrug of nalidixic acid. Drug Dev Ind Pharm 2001;27:331-336
46. Pradhan A, Majumdar MK. Metabolism of some drugs by intestinal lactobacilli and their toxicological considerations. Acta Pharmacol Toxicol (Copenh) 1986;58:11-15
47. Nolen HW III, Friend DR. Menthol-beta-D-glucuronide: a potential prodrug for treatment of the irritable bowel syndrome. Pharm Res 1994;11:1707-1711
48. Simpkins JW, Smulkowski M, Dixon R, et al. Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates. J Pharmacol Exp Ther 1988;244:195-205
49. Rodrigues CM, Kren BT, Steer CJ, et al. The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation. Gastroenterology 1995;109:1835-1844
50. Lee JS, Jung YJ, Kim YM. Synthesis and evaluation of N-acyl-2-(5- fluorouracil-1-yl)-D,L-glycine as a colon-specific prodrug of 5-fluorouracil. J Pharm Sci 2001;90:1787-1794
51. Kim H, Kong H, Choi B, et al. Metabolic and pharmacological properties of rutin, a dietary quercetin glycoside, for treatment of inflammatory bowel disease. Pharm Res 2005;22:1499-1509
52. Kobashi K, Nishimura T, Kusaka M, et al. Metabolism of sennosides by human intestinal bacteria. Planta Med 1980;40:225-236
53. Krishnaiah YS, Veer Raju P, Dinesh Kumar B, et al. Development of colon targeted drug delivery systems for mebendazole. J Control Release 2001;77:87-95
54. Krishnaiah YS, Satyanarayana V, Kumar BD, et al. Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer. J Drug Target 2002;10:247-254
55. Sinha VR, Bhinge JR, Kumria R, et al. Development of pulsatile systems for targeted drug delivery of celecoxib for prophylaxis of colorectal cancer. Drug Deliv 2006;13:221-225
56. Tozaki H, Nishioka J, Komoike J, et al. Enhanced absorption of insulin and (Asu(1,7))eel-calcitonin using novel azopolymer-coated pellets for colon-specific drug delivery. J Pharm Sci 2001;90:89-97
57. Tozaki H, Komoike J, Tada C, et al. Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J Pharm Sci 1997;86:1016-1021
58. Van den Mooter G, Maris B, Samyn C, et al. Use of azo polymers for colon-specific drug delivery. J Pharm Sci 1997;86:1321-1327
59. Larsen C, Jensen BH, Olesen HP. Bioavailability of ketoprofen from orally administered ketoprofen-dextran ester prodrugs in the pig. Acta Pharm Nord 1991;3:71-76
60. Robinson MG. New oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease. Gastroenterol Clin North Am 1989;18:43-50
61. Chan RP, Pope DJ, Gilbert AP, et al. Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide. Dig Dis Sci 1983;28:609-615
62. Yamaguchi T, Sasaki K, Kurosaki Y, et al. Biopharmaceutical evaluation of salicylazosulfanilic acid as a novel colon-targeted prodrug of 5-aminosalicylic acid. J Drug Target 1994;2:123-131
63. Dhaneshwar SS, Gairola N, Kandpal M, et al. Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrug of 5-aminosalicylic acid with D-phenylalanine for colon specific drug delivery in inflammatory bowel disease. Bioorg Med Chem Lett 2007;17:1897-1902 (Pubitemid 46367669)
64. Lu ZR, Shiah JG, Sakuma S, et al. Design of novel bioconjugates for targeted drug delivery. J Control Release 2002;78:165-173
65. Canevari M, Castagliuolo I, Brun P, et al. Poly(ethylene glycol)-mesalazine conjugate for colon specific delivery. Int J Pharm 2009;368:171-177
66. Davaran S, Hanaee J, Khosravi A. Release of 5-amino salicylic acid from acrylic type polymeric prodrugs designed for colon-specific drug delivery. J Control Release 1999;58:279-287
67. Pellicciari R, Garzon-Aburbeh A, Natalini B, et al. Brush-border-enzyme- mediated intestine-specific drug delivery. Amino acid prodrugs of 5-aminosalicylic acid. J Med Chem 1993;36:4201-4207
68. Jung Y, Kim HH, Kim H, et al. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis. Eur J Pharm Sci 2006;28:26-33
69. Kim H, Huh J, Jeon H, et al. N,N'-Bis (5-aminosalicyl)-L-cystine is a potential colon-specific 5-aminosalicylic acid prodrug with dual therapeutic effects in experimental colitis. J Pharm Sci 2009;98:159-168
70. Kim H, Jeon H, Kong H, et al. A molecular mechanism for the anti-inflammatory effect of taurine-conjugated 5-aminosalicylic acid in inflamed colon. Mol Pharmacol 2006;69:1405-1412
71. Jung YJ, Lee JS, Kim HH, et al. Synthesis and properties of dextran-5-aminosalicylic acid ester as a potential colon-specific prodrug of 5-aminosalicylic acid. Arch Pharm Res 1998;21:179-186
72. Inoue M, Morikawa M, Tsuboi M, et al. Species difference and characterization of intestinal esterase on the hydrolizing activity of ester-type drugs. Jpn J Pharmacol 1979;29:9-16
73. Larsen C, Harboe E, Johansen M, et al. Macromolecular prodrugs. XVI. Colon-targeted delivery-comparison of the rate of release of naproxen from dextran ester prodrugs in homogenates of various segments of the pig gastrointestinal (GI) tract. Pharm Res 1989;6:995-999
74. Herzog R, Leuschner J. Experimental studies on the pharmacokinetics and toxicity of 5-aminosalicylic acid-O-sulfate following local and systemic application. Arzneimittelforschung 1995;45:300-303
75. Crotty B, Jewell DP. Drug therapy of ulcerative colitis. Br J Clin Pharmacol 1992;34:189-198
76. Friend DR, Chang GW. Drug glycosides: potential prodrugs for colon-specific drug delivery. J Med Chem 1985;28:51-57
77. Conchie J, Macdonald DC. Glycosidases in the mammalian alimentary tract. Nature 1959;184(Suppl 16):1233
78. Haeberlin B, Rubas W, Nolen HW III, et al. In vitro evaluation of dexamethasone-beta-D-glucuronide for colon-specific drug delivery. Pharm Res 1993;10:1553-1562
79. Cui N, Friend DR, Fedorak RN. A budesonide prodrug accelerates treatment of colitis in rats. Gut 1994;35:1439-1446
80. Jung YJ, Doh MJ, Kim IH, et al. Prednisolone 21-sulfate sodium: a colon-specific pro-drug of prednisolone. J Pharm Pharmacol 2003;55:1075-1082
81. Kong H, Kim Y, Lee Y, et al. Sulfate-conjugated methylprednisolone: evaluation as a colon-specific methylprednisolone prodrug and comparison with sulfate-conjugated prednisolone and dexamethasone. J Drug Target 2009;17:159-167
82. Kim I, Kong H, Lee Y, et al. Dexamethasone 21-sulfate improves the therapeutic properties of dexamethasone against experimental rat colitis by specifically delivering the steroid to the large intestine. Pharm Res 2009;26:415-421
83. Kong H, Lee Y, Hong S, et al. Sulfate-conjugated methylprednisolone as a colon-targeted methylprednisolone prodrug with improved therapeutic properties against rat colitis. J Drug Target 2009;17:450-458
84. McLeod AD, Friend DR, Tozer TN. Glucocorticoid-dextran conjugates as potential prodrugs for colon-specific delivery: hydrolysis in rat gastrointestinal tract contents. J Pharm Sci 1994;83:1284-1288
85. McLeod AD, Fedorak RN, Friend DR, et al. A glucocorticoid prodrug facilitates normal mucosal function in rat colitis without adrenal suppression. Gastroenterology 1994;106:405-413
86. Yano H, Hirayama F, Arima H, et al. Preparation of prednisolone-appended alpha-, beta-and gamma-cyclodextrins: substitution at secondary hydroxyl groups and in vitro hydrolysis behavior. J Pharm Sci 2001;90:493-503
87. Yano H, Hirayama F, Kamada M, et al. Colon-specific delivery of prednisolone-appended alpha-cyclodextrin conjugate: alleviation of systemic side effect after oral administration. J Control Release 2002;79:103-112
88. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989;16:215-237
89. Mukherjee KL, Heidelberger C. Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14. J Biol Chem 1960;235:433-437
90. Ho DH, Townsend L, Luna MA, et al. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate. Anticancer Res 1986;6:781-784
91. Lee J, Rho J, Yang Y, et al. Synthesis and in vitro evaluation of N-nicotinoylglycyl-2-(5-fluorouracil-1-yl)-D,L-glycine as a colon-specific prodrug of 5-fluorouracil. J Drug Target 2007;15:199-205
92. Jung YJ, Kim HH, Kong HS, et al. Synthesis and properties of 5-aminosalicyl-taurine as a colon-specific prodrug of 5-aminosalicylic acid. Arch Pharm Res 2003;26:264-269
93. Brondsted H, Kopecek J. Hydrogels for site-specific drug delivery to the colon: in vitro and in vivo degradation. Pharm Res 1992;9:1540-1545
94. Dubin P, Wright KL. Reduction of azo food dyes in cultures of Proteus vulgaris. Xenobiotica 1975;5:563-571
95. Shamat MA. The role of the gastrointestinal microflora in the metabolism of drugs. Int J Pharm 1993;97:1-13
96. Kim IH, Kong HS, Choi BI, et al. Synthesis and in vitro properties of dexamethasone 21-sulfate sodium as a colon-specific prodrug of dexamethasone. Drug Dev Ind Pharm 2006;32:389-397
97. Basit AW, Newton JM, Lacey LF. Susceptibility of the H2-receptor antagonists cimetidine, famotidine and nizatidine, to metabolism by the gastrointestinal microflora. Int J Pharm 2002; 237:23-33
98. Jung YJ, Lee JS, Kim YM. Colon-specific prodrugs of 5-aminosalicylic acid: synthesis and in vitro/in vivo properties of acidic amino acid derivatives of 5-aminosalicylic acid. J Pharm Sci 2001;90:1767-1775
99. Zhou SY, Fleisher D, Pao LH, et al. Intestinal metabolism and transport of 5-aminosalicylate. Drug Metab Dispos 1999;27:479-485
100. Christrup LL, Moss J, Steffansen B. Prodrugs. In: Swarbrick J, Boylan JC, editors, Encyclopedia of pharmaceutical technology. Volume 13. Marcel Dekker, Inc.; 1988. p. 39-70
101. Stella VJ. Case for prodrugs. In: Stella VJ, Borchardt RT, Hageman MJ, et al., editors, Prodrugs: challenges and rewards. New York: Springer Science; 2007. p. 3-36
102. Gao SQ, Lu ZR, Petri B, et al. Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a 1,6-elimination spacer. J Control Release 2006;110:323-331
103. Hiipakka RA, Zhang HZ, Dai W, et al. Structure-activity relationships for inhibition of human 5alpha-reductases by polyphenols. Biochem Pharmacol 2002;63:1165-1176
104. Ojima M, Satoh K, Gomibuchi T, et al. The inhibitory effects of glycyrrhizin and glycyrrhetinic acid on the metabolism of cortisol and prednisolone-in vivo and in vitro studies. Nippon Naibunpi Gakkai Zasshi 1990;66:584-596
105. Yuan H, Ji WS, Wu KX, et al. Anti-inflammatory effect of Diammonium Glycyrrhizinate in a rat model of ulcerative colitis. World J Gastroenterol 2006;12:4578-4581